product summary
Loading...
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
MGMT Monoclonal Antibody (MT23.2)
catalog :
35-7000
quantity :
100 µg
price :
US 425.00
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
MT23.2
reactivity :
human
application :
western blot, immunohistochemistry, immunocytochemistry, flow cytometry, immunohistochemistry - paraffin section
more info or order :
Invitrogen product webpage
citations: 17
Published Application/Species/Sample/DilutionReference
  • immunohistochemistry - paraffin section; human; fig 3
Munthe S, Petterson S, Dahlrot R, Poulsen F, Hansen S, Kristensen B. Glioma Cells in the Tumor Periphery Have a Stem Cell Phenotype. PLoS ONE. 2016;11:e0155106 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:100; fig 4
Jakacki R, Cohen K, Buxton A, Krailo M, Burger P, Rosenblum M, et al. Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study. Neuro Oncol. 2016;18:1442-50 pubmed publisher
  • western blot; human
Leng S, Wu G, Collins L, Thomas C, Tellez C, Jauregui A, et al. Implication of a Chromosome 15q15.2 Locus in Regulating UBR1 and Predisposing Smokers to MGMT Methylation in Lung. Cancer Res. 2015;75:3108-17 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:100; fig 1
Bengtsson D, Schrøder H, Andersen M, Maiter D, Berinder K, Feldt Rasmussen U, et al. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. J Clin Endocrinol Metab. 2015;100:1689-98 pubmed publisher
  • immunocytochemistry; human; 1:50
  • western blot; human; 1:50
Castro G, Cayado Gutiérrez N, Zoppino F, Fanelli M, Cuello Carrión F, Sottile M, et al. Effects of temozolomide (TMZ) on the expression and interaction of heat shock proteins (HSPs) and DNA repair proteins in human malignant glioma cells. Cell Stress Chaperones. 2015;20:253-65 pubmed publisher
  • western blot; human; 1:125
Qiu Z, Shen D, Chen Y, Yang Q, Guo C, Feng B, et al. Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells. Chin J Cancer. 2014;33:115-22 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:50; fig 4
Castro G, Cayado Gutiérrez N, Moncalero V, Lima P, De Angelis R, Chavez V, et al. Hsp27 (HSPB1): a possible surrogate molecular marker for loss of heterozygosity (LOH) of chromosome 1p in oligodendrogliomas but not in astrocytomas. Cell Stress Chaperones. 2012;17:779-90 pubmed publisher
  • flow cytometry; human; tbl 1
  • immunohistochemistry; human
Brell M, Ibanez J, Tortosa A. O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction. BMC Cancer. 2011;11:35 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:100; fig 6
Horbinski C, Hamilton R, Lovell C, Burnham J, Pollack I. Impact of morphology, MIB-1, p53 and MGMT on outcome in pilocytic astrocytomas. Brain Pathol. 2010;20:581-8 pubmed publisher
  • immunohistochemistry - paraffin section; human; fig 3
Cooper W, Kohonen Corish M, Chan C, Kwun S, McCaughan B, Kennedy C, et al. Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small-cell lung cancer and precursor lesions. Histopathology. 2008;52:613-22 pubmed publisher
Boyd N, Walker K, Fried J, Hackney J, McDonald P, Benavides G, et al. Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo. JCI Insight. 2017;2: pubmed publisher
Pietanza M, Kadota K, Huberman K, Sima C, Fiore J, Sumner D, et al. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res. 2012;18:1138-45 pubmed publisher
Cohen K, Pollack I, Zhou T, Buxton A, Holmes E, Burger P, et al. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol. 2011;13:317-23 pubmed publisher
Pollack I, Hamilton R, Sobol R, Nikiforova M, Nikiforov Y, Lyons Weiler M, et al. Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2010;55:1066-71 pubmed publisher
Kuester D, El Rifai W, Peng D, Ruemmele P, Kroeckel I, Peters B, et al. Silencing of MGMT expression by promoter hypermethylation in the metaplasia-dysplasia-carcinoma sequence of Barrett's esophagus. Cancer Lett. 2009;275:117-26 pubmed publisher
Pollack I, Hamilton R, Sobol R, Burnham J, Yates A, Holmes E, et al. O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J Clin Oncol. 2006;24:3431-7 pubmed
Schildhaus H, Kröckel I, Lippert H, Malfertheiner P, Roessner A, Schneider Stock R. Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach. Int J Oncol. 2005;26:1493-500 pubmed
product information
Product Type :
Antibody
Product Name :
MGMT Monoclonal Antibody (MT23.2)
Catalog # :
35-7000
Quantity :
100 µg
Price :
US 425.00
Clonality :
Monoclonal
Purity :
protein A
Host :
Mouse
Reactivity :
Human
Applications :
Immunocytochemistry: 2 µg/mL, Immunohistochemistry: Assay-dependent, Western Blot: 2 µg/mL
Species :
Human
Clone :
MT23.2
Isotype :
IgG2b
Storage :
-20°C
Description :
O6-Methylguanine-DNA Methyltransferase (MGMT) is an important DNA repair protein involved in tumor cell resistance to the cytostatic activity of chemotherapeutic alkylating agents. This protein is also effective in protecting normal cells against the genotoxic and carcinogenic effects of DNA alkylation. The alkylating drug resistance is caused by MGMT's ability to remove DNA alkyl groups introduced in the O6 position of guanine. MGMT is expressed in highly variable amounts, depending upon the cell and tissue type, species, and cellular growth characteristics. In addition, MGMT activity varies among groups of tumors and within a particular type of tumor.
Immunogen :
Recombinant human MGMT
Format :
Liquid
Applications w/Dilutions :
Immunocytochemistry: 2 µg/mL, Immunohistochemistry: Assay-dependent, Western Blot: 2 µg/mL
Aliases :
0-6-methylguanine-DNA methyltransferase; 6-O-methylguanine-DNA methyltransferase; Agat; AGT; AI267024; methylated DNA protein cysteine methyltransferase; methylated-DNA--protein-cysteine methyltransferase; methylguanine-DNA methyltransferase; MGMT; O(6)-alkylguanine-DNA alkyltransferase; O-6-alkylguanine-DNA alkyltransferase; O6-alkylguanine-DNA alkyltransferase; O-6-methylguan; O6-methylguanine-DNA methyltranferase; O-6-methylguanine-DNA methyltransferase; O6-methylguanine-DNA methyltransferase; O-6-methylguanine-DNA-alkyltransferase
more info or order :
Invitrogen product webpage
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com
800-678-5599
headquarters: USA